98 Chapter 4 Sensitivity Specificity PPV NPV n/N % 95% CI n/N % 95% CI % 95% CI % 95% CI ASCL1 methylation 44/86 51.2% (40.6-61.7%) 408/507 80.5% (77.0-83.9%) 30.8% (23.2-38.3%) 90.7% (88.0-93.4%) LHX8 methylation 56/86 65.1% (55.0-75.2%) 351/507 69.2% (65.2-73.2%) 26.4% (20.5-32.3%) 92.1% (89.4-94.8%) Marker panel ASCL1/LHX8 63/86 73.3% (63.9-82.6%) 310/507 61.1% (56.9-64.5%) 24.2% (19.0-29.4%) 93.1% (90.4-95.8%) HPV16/18 genotyping 53/72 73.6% (63.4-83.8%) 286/419 68.3% (63.8-72.7%) 28.5% (22.0-35.0%) 93.8% (91.1-96.5%) HPV16/18 genotyping with marker panel ASCL1/LHX8 64/72 88.9% (81.6-96.1%) 239/419 57.0% (52.3-61.8%) 26.2% (20.7-31.7%) 96.8% (94.6-99.0%) Cytology* 78/86 90.7% (84.6-96.8%) 346/507 68.2% (64.2-72.3%) 32.6% (26.7-38.6%) 97.7% (96.2-99.3%) *on paired clinician-collected cervical sample (threshold ASC-US). Abbreviations: n, number of; N, total number of; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HPV, human papillomavirus; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia Table 4.1 Clinical performance fo the detection CIN3+.
RkJQdWJsaXNoZXIy MjY0ODMw